Crysvita(burosumab)
Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia, hypophosphatemic rickets, osteochondrodysplasias, and osteomalacia. The pharmaceutical is active against fibroblast growth factor 23.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Crysvita
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Burosumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Crysvita | burosumab-twza | Kyowa Kirin | N-761068 RX | 2018-04-17 | 3 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| crysvita | Biologic Licensing Application | 2025-09-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
burosumab, Crysvita, Kyowa Kirin, Inc. | |||
| 2026-09-27 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0584 | Injection, burosumab-twza 1 mg |
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Familial hypophosphatemic rickets | D053098 | — | — | 5 | 6 | 7 | 2 | 5 | 22 |
| Hypophosphatemia | D017674 | HP_0002148 | — | 4 | 6 | 5 | 2 | 5 | 19 |
| Osteomalacia | D010018 | EFO_1002027 | M83 | 1 | 2 | 3 | 1 | 1 | 8 |
| Connective tissue neoplasms | D009372 | — | — | — | 2 | — | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypophosphatemic rickets | D063730 | — | E83.31 | 1 | — | 2 | — | 1 | 4 |
| Rickets | D012279 | EFO_0005583 | E55.0 | 1 | — | 2 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nevus | D009506 | EFO_0000625 | — | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 2 | — | — | — | 2 |
| Sebaceous of jadassohn nevus | D054000 | EFO_1001841 | Q82.5 | — | 2 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Burosumab |
| INN | burosumab |
| Description | Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 7VEN |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707326 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14012 |
| UNII ID | G9WJT6RD29 (ChemIDplus, GSRS) |
Target
Agency Approved
FGF23
FGF23
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 786 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,217 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use